Seres Therapeutics (MCRB) Payables: 2015-2025
Historic Payables for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $1.7 million.
- Seres Therapeutics' Payables fell 79.68% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 53.82%. This contributed to the annual value of $4.1 million for FY2024, which is 12.03% up from last year.
- Seres Therapeutics' Payables amounted to $1.7 million in Q3 2025, which was down 23.77% from $2.2 million recorded in Q2 2025.
- Seres Therapeutics' Payables' 5-year high stood at $18.0 million during Q3 2021, with a 5-year trough of $1.7 million in Q3 2025.
- Over the past 3 years, Seres Therapeutics' median Payables value was $4.8 million (recorded in 2024), while the average stood at $6.0 million.
- Per our database at Business Quant, Seres Therapeutics' Payables spiked by 207.13% in 2021 and then tumbled by 79.68% in 2025.
- Quarterly analysis of 5 years shows Seres Therapeutics' Payables stood at $13.7 million in 2021, then surged by 30.29% to $17.9 million in 2022, then slumped by 79.65% to $3.6 million in 2023, then climbed by 12.03% to $4.1 million in 2024, then crashed by 79.68% to $1.7 million in 2025.
- Its last three reported values are $1.7 million in Q3 2025, $2.2 million for Q2 2025, and $2.2 million during Q1 2025.